• RITA (NSC 652287): Optimizing p53 Activation in Cancer Biolo

  2026-07-03

  RITA (NSC 652287) empowers researchers to precisely activate p53 by inhibiting MDM2, unlocking selective cytotoxicity in renal carcinoma and beyond. This guide reveals advanced workflows, troubleshooting strategies, and actionable protocol parameters to leverage RITA’s unique mechanism in apoptosis assays and tumor xenograft models.

• Cefotaxime: Advanced Insights for Multidrug Resistance Resea

  2026-07-03

  Explore the role of Cefotaxime, a third-generation cephalosporin antibiotic, in unraveling multidrug resistance dynamics. This article provides a deeper, experimentally grounded perspective on molecular mechanisms, comparative strategies, and best practices for antimicrobial resistance research.

• Precision p53 Inhibition: Transforming Translational Pain Mo

  2026-07-02

  This thought-leadership article explores how Cyclic Pifithrin-α hydrobromide, a potent p53 inhibitor from APExBIO, offers novel mechanistic and workflow advantages for researchers modeling neuroinflammation and mechanical allodynia in trigeminal neuralgia. Integrating recent discoveries on the CGRP/SP–Piezo2 axis, the piece provides strategic guidance for translational scientists seeking to refine apoptosis inhibition, modulate DNA damage responses, and reduce confounding effects in preclinical studies. Protocol recommendations and a candid assessment of cross-domain maturity are included.

• Nuclear Export Inhibition in TNBC: Synergistic Potential of

  2026-07-02

  The referenced study systematically identifies and characterizes nuclear export inhibitor-based combination therapies for triple-negative breast cancer (TNBC), focusing on the selective CRM1 inhibitor KPT-330 (Selinexor). By integrating high-throughput screening, in vitro synergy assays, and in vivo xenograft models, the research demonstrates that pairing KPT-330 with PI3K/mTOR inhibitors yields superior tumor burden reduction compared to monotherapies, highlighting a promising therapeutic avenue for basal-like TNBC.

• Advances in Antifungal Pipeline: Systematic Review on Candid

  2026-07-01

  This systematic review highlights recent advancements in antifungal drug development targeting multidrug-resistant Candida auris, a pathogen of rising global concern. The findings underscore the efficacy of novel agents—including tetrazoles such as Oteseconazole—in overcoming resistance mechanisms and demonstrate the importance of continual innovation in antifungal therapy.

• Disrupting SARS-CoV-2 Nucleocapsid Phase Separation with GCG

  2026-07-01

  Zhao et al. (2021) revealed that the SARS-CoV-2 nucleocapsid (N) protein undergoes RNA-triggered liquid–liquid phase separation (LLPS), a process vital for viral replication and assembly. The study identifies (-)-gallocatechin gallate (GCG) as a compound that disrupts this phase separation, thus inhibiting viral replication and suggesting a novel antiviral strategy.

• CX-5461 Induces Mitotic Catastrophe in Cervical Cancer Cells

  2026-06-30

  This study demonstrates that CX-5461, an RNA polymerase I inhibitor, suppresses cervical cancer cell proliferation by inducing DNA damage, activating the ATM/ATR pathway, and triggering mitotic catastrophe. The findings establish a mechanistic link between ribosome biogenesis inhibition and enhanced cisplatin sensitivity, providing a rationale for combinatorial therapy in treatment-resistant cervical cancer.

• MK-0812: Precision Monocyte Trafficking Inhibition in MASH R

  2026-06-30

  MK-0812 empowers researchers to dissect CCR2-mediated monocyte trafficking, a central inflammatory driver in gut–liver axis disorders like MASH. This guide translates pivotal study insights into practical workflows, troubleshooting strategies, and optimized protocol parameters for advanced inflammation research.

• Intravesical p21 mRNA-LNP: Localized Tumor Suppressor Therap

  2026-06-29

  This study introduces a non-viral strategy for bladder cancer therapy by delivering p21 mRNA encapsulated in lipid nanoparticles directly into the bladder. The approach restores tumor suppressor activity in situ, markedly reducing tumor growth and demonstrating a practical, localized alternative to systemic mRNA therapeutics.

• Melittin: Precision GPCR Modulation for Translational Oncolo

  2026-06-29

  Explore how Melittin, a bioactive peptide, empowers translational researchers to dissect G protein-coupled receptor (GPCR) signaling in cancer biology. This article bridges mechanistic insight on lipid signaling and ferroptosis resistance in glioblastoma with actionable guidance for leveraging Melittin in advanced signal transduction and apoptosis research. Learn how Melittin’s dual Gs inhibition and Gi stimulation profile offers unique experimental advantages, and discover protocol parameters, translational implications, and future outlook for the field.

• (-)-JQ1: Precision Negative Control for BET Bromodomain Stud

  2026-06-28

  (-)-JQ1, the inactive JQ1 stereoisomer, is indispensable for rigorous BET bromodomain inhibition experiments in epigenetics and cancer biology research. This article unpacks practical workflows, troubleshooting, and protocol parameters that maximize data fidelity and interpretability when using (-)-JQ1 as a negative control.

• Decitabine in Immune Modulation: Beyond Cancer Epigenetics

  2026-06-27

  Explore how Decitabine (5-Aza-2'-deoxycytidine) transforms immunological research by restoring immune tolerance and rebalancing T-cell subsets. This article reveals underappreciated applications in immune homeostasis and practical assay design, setting it apart from conventional cancer epigenetics discussions.

• Okadaic Acid: Technical Guide for Phosphatase 1 Inhibition

  2026-06-26

  Okadaic acid is a potent, marine-derived inhibitor of serine/threonine protein phosphatases, enabling precise modulation of PP1 and PP2A activity in cell signaling, apoptosis, and cancer research. It is best suited for controlled laboratory workflows requiring selective inhibition; use in non-standard solvent systems or where broad phosphatase inhibition is needed should be avoided.

• Spermine: Applied Protocols for Ion Channel and Fusion Resea

  2026-06-26

  Harness the multifaceted power of Spermine, an endogenous polyamine, for advanced studies in ion channel regulation and nuclear membrane dynamics. This guide distills bench-proven workflows, troubleshooting strategies, and the latest cross-domain insights to empower reproducible, high-impact research.

• Ferrostatin-1 (Fer-1): Redefining Ferroptosis Assays in Canc

  2026-06-25

  Explore how Ferrostatin-1 (Fer-1) is transforming ferroptosis assay design and oxidative lipid damage inhibition in cancer biology and neurodegenerative disease models. This article offers a unique, in-depth analysis of Fer-1’s mechanistic role, protocol optimization, and the impact of emergent ROS-based therapies.

16860 records 1/1124 page Next 12345 下5页 Last page